Bifiform caps. ksh / sol. №30
Category
Dysbacteriosis
,
Probiotics and prebiotics
,
Inulins
Scope of the medicinal product
Gastrointestinal tract
Release form
Capsules
Manufacturer country
Italy
Package quantity, pcs
thirty
BififormВ® is an effective drug for the treatment of dysbiosis!
Benefits of the drug:
Studied bacteria: The preparation contains researched, safe and beneficial probiotic bacteria from the leading microbiological laboratory “Christian Hansen” (Denmark).
Two-layer protective shell: The BififormВ® capsule has a two-layer protective shell, thanks to which the entire complex of beneficial probiotic bacteria is delivered to the intestines.
The bacteria are not destroyed by the acidic environment of the stomach and retain their beneficial properties when entering the intestines.
Special nutrient medium for beneficial bacteria: BififormВ®, in addition to beneficial bacteria, contains a special nutrient medium for their nutrition, growth and reproduction.
BififormВ® does not contain lactose
No connection with food intake.
Pharmacological properties
The strains Enterococcus faecium and Bifidobacterium longum, which are part of the preparation, are natural symbiotic bacteria that inhabit the gastrointestinal tract. The drug has a normalizing effect on the quantitative and qualitative composition of the intestinal microflora. The action is due both to the direct direct effect of the components included in the drug (high antagonistic activity against pathogenic and opportunistic microorganisms), and indirectly - stimulation of the local intestinal link of immunity (activation of the synthesis of immunoglobulin A, induction of the synthesis of endogenous interferon).
Bifidobacterium longum has a high survival rate in the human intestine and a high growth rate.
The inclusion in the preparation of the apathogenic enterococcus Enterococcus faecium, which normally colonizes the small intestine, makes it possible to have a positive effect on the condition and digestive functions of not only the large, but also the small intestine, especially in the presence of fermentative dyspepsia and the phenomena of flatulence.
Name ENG
BIFIFORM
Clinical and pharmacological group
A drug that regulates the balance of intestinal microflora (probiotic)
ATX code
Antidiarrheal drugs of biological origin, regulating the balance of intestinal microflora
Dosage
at least 107 bacterial cells
Structure
1 enteric capsule contains:
Active ingredients:
Enterococcus faecium at least 1?
107 CFU
Bifidobacterium longum at least 1?
107 CFU
Excipients:
anhydrous dextrose 162.5 mg, yeast starter culture 17.5 mg, locust bean gum 12.5 mg, magnesium stearate 2.5 mg, lactulose 0.5 mg.
The composition of the capsule shell:
gelatin 48.0 mg, titanium dioxide (0.96 mg) *, magnesium stearate 0.5 mg, methacrylic acid and methyl methacrylate copolymer [1: 1] 2.2 mg, methacrylic acid and ethyl acrylate copolymer [1: 1] [30 % dispersion] 7.7 mg, talc 5.6 mg, macrogol 6000 1.5 mg, refined soybean oil 0.8 mg, diacetylated glycerides 0.3 mg.
* The weight of titanium dioxide is included in the total weight of the gelatin capsule.
Indications
- diarrhea caused by acute and exacerbation of chronic gastroenteritis, rotavirus infection
antibiotic-associated diarrhea
traveler's diarrhea, in the complex therapy of acute intestinal infections.
In the complex therapy of chronic diseases of the gastrointestinal tract, such as colitis, irritable bowel syndrome and other gastrointestinal disorders of functional genesis.
Normalization of intestinal microflora, treatment and prevention of dysbacteriosis and maintenance of the immune system in children over 2 years of age and adults.
Lactose intolerance.
As part of a comprehensive standard eradication therapy in patients with Helicobacter pylori infection.
INN / Active ingredient
Enterococcus fetium + bifidobacterium longum
Storage conditions and periods
In a dry place, at a temperature not exceeding 25 degrees.
Expiration date: 2 years
Contraindications
Individual hypersensitivity to drug components
Specifications
Category
Dysbacteriosis
,
Probiotics and prebiotics
,
Inulins
Scope of the medicinal product
Gastrointestinal tract
Release form
Capsules
Manufacturer country
Italy
Package quantity, pcs
thirty
Scope of application
Gastroenterology
Minimum age from
2 years old
Way of introduction
Through the mouth
Vacation conditions
Without recipe
Brand name
Bifiform
The amount of the dosage form in the primary package
30 pcs.
Primary packaging type
Pencil case
Type of consumer packaging
Pack of cardboard
Pharmaco-therapeutic group
Eubiotic
Anatomical and therapeutic characteristics
A07FA Antidiarrheal microorganisms
Dosage form
Enteric capsules
Dosage (volume) of the substance in the preparation
at least 107 bacterial cells
The target audience
Children
Expiration date in days
730
Package weight, g
45
Mode of application
:
Bifiform is prescribed for adults and children from 2 years of age, 2-3 capsules per day.
If necessary, the daily dose can be increased to 4 capsules. < br> In the treatment of gastrointestinal disorders, the antidiarrheal effect is achieved, as a rule, on the first day of drug use. < br> The course of treatment of acute diarrhea can be 2-3 days.
In other cases, the course of treatment is 10-21 days. < br> Take regardless of the meal.
Information on technical characteristics, delivery set, country of manufacture